血小板与淋巴细胞比值在非小细胞肺癌患者预后评估中的价值  

Value of platelets-lymphocyte ratio in prognosis evaluation of non-small cell lung cancer patients

作　　者：李鹏[1] 闫相涛[1] 张国伟[1] 张米娜[1] 王慧娟[1] 马智勇[1] 

机构地区：[1]郑州大学附属肿瘤医院/河南省肿瘤医院,450008

出　　处：《中国实用医药》2016年第13期5-7,共3页China Practical Medicine

摘　　要：目的探讨血小板与淋巴细胞比值(PLR)和中性粒细胞与淋巴细胞比值(NLR)在接受化疗的非小细胞肺癌(NSCLC)患者中对无进展生存时间(PFS)的影响。方法回顾性分析具有完整随访资料的90例患者,均由病理证实为NSCLC,均接受含铂双药方案化疗,应用生存分析,探讨影响PFS的因素。结果在单因素分析中,病理类型、NLR及PLR与中位PFS显著相关。经过COX多元回归模型校正分析,病理类型、转移脏器数目、PLR与不良的预后相关。结论在接受化疗的NSCLC患者中,PLR具有预测PFS的作用,但仍需大样本、前瞻性数据证实本研究结果。ObjectiveTo investigate influence by platelets-lymphocyte ratio （PLR） and neutrophil-lymphocyte ratio （NLR） on progression-free survival （PFS） in non-small cell lung cancer （NSCLC） patients under chemotherapy.MethodsA retrospective analysis was made on complete follow-up data of 90 patients. All patients were pathologically confirmed as NSCLC, and they all received platinum-based double medicine chemotherapy. Survival analysis was made on influencing factors for PFS.ResultsUnivariate analysis showed remarkable correlation between pathological pattern, NLR, PLR and median PFS. COX multiple regression model correction showed that pathological pattern, metastasis organ number and PLR were correlated with poor prognosis. ConclusionPLR shows predictive effect for PFS in NSCLC patients under chemotherapy, while large sample and proactive data are necessary for verification of this research.

关 键 词：血小板与淋巴细胞比值 中性粒细胞与淋巴细胞比值 非小细胞肺癌 预后评估 

分 类 号：R734.2[医药卫生—肿瘤]